New pain treatment

Without taking medication.

While companies like Neuralink are betting on surgical robots to implant electrodes directly into the brain, a completely different approach is gaining momentum in China. Instead of opening the skull or inserting chips into the cerebral cortex, researchers have developed a helmet capable of interacting with neurons using only highly focused ultrasound waves; in this case, the goal is not to control computers with the mind, but to treat neurological diseases and alleviate chronic pain without resorting to invasive surgery.

The helmet operates based on the physics of transcranial focused ultrasound. Instead of using electrical signals, the system emits high-frequency acoustic waves capable of passing through the skull and reaching deep regions of the brain with great precision. Artificial intelligence algorithms continuously control the intensity, frequency, and focus of these waves, making it possible to stimulate or suppress the activity of specific groups of neurons. At the same time, sensors monitor the body's response in real time, creating a continuous feedback loop that automatically adjusts the stimulation throughout the session.

The initial clinical results attracted attention precisely because of the technology's therapeutic potential.

In treatment sessions lasting between 30 and 45 minutes, patients suffering from chronic pain showed significant reductions in pain intensity—in some cases approaching 50%—immediately following the procedure. This effect persisted for several days in some participants, raising the possibility of reducing the ongoing use of potent painkillers, particularly opioids. Conditions such as post-herpetic neuralgia, fibromyalgia, and other pain syndromes are among the primary targets for this technology, which aims to act directly on the circuits responsible for pain perception rather than simply masking symptoms.

Beyond pain management, studies are already investigating the technology's potential for treating conditions such as treatment-resistant depression, Parkinson's disease, Alzheimer's disease, and epilepsy, as well as for the rehabilitation of stroke patients. While larger-scale clinical studies are still needed to confirm the efficacy and safety of this approach across various conditions, the technology's potential to usher in a new generation of neurological treatments is undeniable.